Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock?
11:05am, Friday, 05'th Dec 2025
Novo Nordisk's semaglutide failed in pivotal studies as a treatment for Alzheimer's disease. This isn't a significant obstacle to the drugmaker's prospects, despite what the market reaction suggests.
India's Healthify eyes more weight-loss drugmaker tie-ups after Novo Nordisk pact
04:55am, Friday, 05'th Dec 2025
Indian health-tech startup Healthify is in talks to partner with more weight-loss drugmakers to offer health, nutrition and lifestyle coaching, after signing a deal with Novo Nordisk's India unit, its
Novo Nordisk Stock Rises -- Alzheimer's Program Hints at Potential Gains
01:48pm, Thursday, 04'th Dec 2025
Novo Nordisk (NVO) rose about 1% on Thursday morning after the Danish drugmaker indicated it may continue testing its pill version of Ozempic for Alzheimer's di
Wegovy's prices are going down, but they are ‘wildly different' — and confusing
12:01pm, Thursday, 04'th Dec 2025
It depends on a patient's medical coverage, of course, but also on an increasingly tangled web of federal policies and corporate pricing strategies, along with the ability to do good old-fashioned res
Novo Nordisk Leans on India After Trial Miss
08:42am, Thursday, 04'th Dec 2025
Novo Nordisk (NVO) is pressing ahead with its Alzheimer's ambitions even after two pill trials for Ozempic came up empty, while quietly gearing up for an India
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment
10:15pm, Wednesday, 03'rd Dec 2025
Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wedne
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment
08:06pm, Wednesday, 03'rd Dec 2025
Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wedne
Novo Nordisk gears up for December Ozempic launch in India, sources say
12:55pm, Wednesday, 03'rd Dec 2025
Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar with the matter said, as it seeks to strengthen its foothold in the world's
Inside Biotech: TGA raises a red flag on GLP-1 drugs — but uncertainty remains
12:04pm, Wednesday, 03'rd Dec 2025
The booming weight-loss drug market felt a jolt in Australia on Tuesday, when the Therapeutic Goods Administration issued a safety alert warning of...
Medicare Just Cut the Price of Wegovy: Should You Sell Novo Nordisk Stock?
09:30am, Wednesday, 03'rd Dec 2025
The government has just negotiated a significant price reduction for the diabetes and weight-loss treatment. The stock jumped following this news, signaling that it's not as bad as it seems at first g
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
03:42pm, Tuesday, 02'nd Dec 2025
Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday,
Here's Why Novo Nordisk Just Paid $2.1 Billion For Zaltenibart
02:20pm, Tuesday, 02'nd Dec 2025
Novo Nordisk A/S has acquired Zaltenibart, a Phase 2 MASP-3 inhibitor, for up to $2.1 billion, signaling strong conviction in its long-term potential. NVO shares have declined ~20% since October, now
Novo's $1 Billion Obesity Bet Just Took a Shocking Turn--And It Starts With 8-Year-Olds
11:23am, Tuesday, 02'nd Dec 2025
Novo Nordisk (NVO) is moving into its next chapter with CagriSema, and the pivot could be more ambitious than many investors expected. Despite recent adult stud
Novo Nordisk to test next-gen obesity drug CagriSema in children
10:50am, Tuesday, 02'nd Dec 2025
Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children and adolescents, according to a U.S. registry of clinical trials.
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
10:01am, Tuesday, 02'nd Dec 2025
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
